<DOC>
	<DOCNO>NCT00229918</DOCNO>
	<brief_summary>Prospective randomize clinical trial compare Laser Alone v. Laser posterior sub-tenon injection triamcinolone acetonide primary refractory clinically significant macular edema .</brief_summary>
	<brief_title>PST/Laser v. Laser Alone CSME</brief_title>
	<detailed_description>Clinically significant macular edema ( CSME ) one lead cause vision loss diabetic retinopathy . The current standard care CSME focal/grid laser photocoagulation . However , many patient experience vision loss and/or require multiple laser treatment . In recent study , intraocular ( intravitreal ) injection triamcinolone acetonide show beneficial CSME , however , risk procedure include endophthalmitis increase risk steroid-induced intraocular pressure ( IOP ) elevation . Posterior sub-Tenon injection ( PST ) triamcinolone acetonide commonly use inflammatory condition eye recently , increasingly use diabetic macular edema . The objective study determine whether combined treatment PST triamcinolone acetonide laser photocoagulation CSME decrease rate moderate vision loss , increase visual gain , decrease central macular thickness compare laser photocoagulation alone . Both primary ( previous history focal/grid laser ) refractory ( previous history focal/grid laser ) CMSE study . Thirty ( 30 ) eye primary CSME thirty ( 30 ) eye refractory CSME randomize one two group : 1 ) PST/Laser group 2 ) Laser alone group . All patient Optical Coherence Tomography ( OCT ) initial final visit . Patients assign PST/Laser group use topical steroid ( 1 % prednisolone acetate ) four time day two week . Patients elevate IOP topical steroid receive PST steroid injection . Following treatment , patient evaluate 1 2 month dilate eye exam , visual acuity , assessment IOP . Moderate vision loss ( loss 15 ETDRS letter ) , vision gain ( ETDRS letter ) , central macular thickness ( measure OCT ) compare group . Multivariate analysis also use compare outcomes two arm study .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>The criterion list must satisfy order patient eligible study . Age 25 80 , inclusive . Primary CSME : CSME secondary diabetic retinopathy define ETDRS one eye previous history focal/grid laser photocoagulation . Refractory CSME : CSME secondary diabetic retinopathy define ETDRS one eye least one session focal/grid laser photocoagulation . Additionally , eye must central macular thickness least 300 μM ( normal , 200 μM ) measure OCT vision loss baseline . All patient Hines VA Eye Clinic suspicion CSME refer Hines VA Retina Clinic evaluate Retina specialist ( Dr. De Alba ) diagnosis CSME confirm clinical examination fluorescein angiography . If exclusion criterion list is/are present , patient eligible study . Unwilling unable give consent . Unable return schedule followup visit . No light perception , light perception , count finger , hand motion vision . History glaucoma ( form ) . History ocular hypertension . History IOP elevation ocular and/or systemic steroid treatment . Baseline IOP great 22 mmHg . All patient IOP elevation great 22 mmHg follow treatment topical prednisolone acetate . All patient IOP elevation great 5 mmHg baseline measurement follow treatment topical Prednisolone acetate . Advanced proliferative diabetic retinopathy . History retinal detachment either eye . Any ocular disease ( anterior posterior segment ) obstruct view fundus ( i.e. , dense cataract , vitreous hemorrhage ) . History PST intravitreal triamcinolone acetonide injection either eye six month prior study . History 20/200 vision bad cause fellow eye . Active inflammatory , infectious , idiopathic keratitis .</criteria>
	<gender>Male</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>Clinically significant macular edema</keyword>
</DOC>